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Introduction
Since the 1940s, the incidence rates of reported cases of
tetanus and tetanus-related deaths have decreased steadily (1).
The decrease has been attributed primarily to universal vacci-
nation with tetanus toxoid (i.e., diphtheria and tetanus tox-
oids and whole-cell pertussis vaccine-pediatric [DTP],
diphtheria and tetanus toxoids and acellular pertussis vaccine-
pediatric [DTaP], pediatric diphtheria and tetanus toxoids
[DT], and adult tetanus and diphtheria toxoids [Td]). How-
ever, improved wound management and childbirth practices
have also contributed to the decrease in reported cases and
deaths from tetanus (2–4).
All 50 states have legal requirements that children receive at
least a primary series (i.e., 3 doses) of tetanus toxoid before
entering school (5). In 2000, results of the National Immuni-
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Abstract
Problem/Condition: Tetanus is a severe and often fatal infection. The incidence of reported cases in the United States
has declined steadily since introduction of tetanus toxoid vaccines in the 1940s.
Reporting Period: This report covers surveillance data for 1998–2000.
Description of System: Physician-diagnosed cases of tetanus were reported to CDC’s National Notifiable Disease
Surveillance System. Supplemental clinical and epidemiologic information were provided by states.
Results and Interpretation: During 1998–2000, an average of 43 cases of tetanus was reported annually; the average
annual incidence was 0.16 cases/million population. The highest average annual incidence of reported tetanus was
among persons aged >60 years (0.35 cases/million population), persons of Hispanic ethnicity (0.37 cases/million popu-
lation), and older adults known to have diabetes (0.70 cases/million population). Fifteen percent of the cases were
among injection-drug users. The case-fatality ratio was 18% among 113 patients with known outcome; 75% of the
deaths were among patients aged >60 years. No deaths occurred among those who were up-to-date with tetanus toxoid
vaccination. Seventy-three percent of 129 cases with known injury information available reported an acute injury; of
these, only 37% sought medical care for the acute injury, and only 63% of those eligible received tetanus toxoid for
wound prophylaxis.
Interpretation: The majority of tetanus cases occurred among persons inadequately vaccinated or with unknown
vaccination history who sustained an acute injury. Adults aged >60 years were at highest risk for tetanus and tetanus-
related death.
Public Health Actions: Tetanus is preventable through routine vaccination (i.e., primary series and decennial boosters)
and appropriate management. A shortage of tetanus and diphtheria toxoids vaccine that began during 2000 ended in
2002. Efforts by health-care providers are warranted to vaccinate persons with delayed or incomplete vaccination, with
emphasis on older persons and persons with high-risk conditions.
zation Survey indicated that 94% of children aged 19–35
months had received 3 doses of tetanus toxoid (6). In con-
trast to the high vaccination rates among young children, the
1998 National Health Interview Survey indicated that only
40% of adults aged >65 years had received a booster dose of
tetanus toxoid during the previous 10 years (7) as recom-
mended by the Advisory Committee on Immunization Prac-
tices (ACIP) (8). Moreover, only 31% of adults aged >70 years
whose serum was tested during 1988–1994 for the Third
National Health and Nutrition Examination Survey had pro-
tective titers of antibody to tetanus toxin (9,10).
National surveillance for tetanus is conducted to monitor
the trends in disease and the effectiveness of the vaccination
program. This report is an analysis of the epidemiology of
tetanus in the United States during 1998–2000.
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Methods
Tetanus Surveillance
National tetanus surveillance is a passive system that relies
on physicians to report cases of tetanus to state and local health
departments. Because no laboratory test provides definitive
diagnosis of tetanus, the diagnosis of tetanus is based on the
clinical judgment of the attending physician. In 1990, the
Council of State and Territorial Epidemiologists and CDC
adopted a clinical case definition for public health surveil-
lance of tetanus, which is the acute onset of hypertonia and/
or painful muscular contractions (usually of the jaw and neck
muscles) and generalized muscle spasms without other appar-
ent medical cause (as reported by a health professional) (11).
State and local health departments report cases of tetanus
weekly to the National Notifiable Diseases Surveillance Sys-
tem (NNDSS). The reports are transmitted to CDC through
the National Electronic Telecommunications System for Sur-
veillance (NETSS) and contain supplemental clinical and
epidemiologic information for each case. Supplemental
information includes the clinical history; presence and nature
of any associated risk factors; the patient’s vaccination status,
wound care, and clinical management; and outcome for each
case of tetanus. CDC contacted state and local health depart-
ments for additional unreported tetanus cases and included
13 cases in this surveillance summary not initially reported to
NNDSS.
Data Analysis
For the calculation of rates of reported tetanus cases per
million population by demographic variables, the denomina-
tor population used was the mid-year resident population
estimates during 1998–2000 (12). For the calculation of rates
of tetanus cases per million persons known to have diabetes
by age group, the denominator population represented a
weighted estimate of persons known to have diabetes obtained
from the 1998–2000 National Health Interview Survey
(13–15).
Results
Long-Term Trends in Morbidity
and Mortality
The average annual number of tetanus cases during 1998–
2000 was 43 — 45 cases in 1998, 42 in 1999, and 43 in
2000. The lowest average annual number of cases for a
3-year period in the United States since tetanus became
reportable in 1947 was 41 cases per year during 1995–1997
(1). The average annual incidence rate during 1998–2000 was
0.16 cases per million population, approximately the same as
the average annual rate during 1995–1997 (0.15 cases per
million population). The incidence rate during 1998–2000
was a 96% decrease from 3.9 cases per million population
reported in 1947 (Figure 1). The case-fatality ratio during
1998–2000 was 18% (20 deaths) for 113 patients with known
outcome; the case-fatality ratio was 11% during 1995–1997
(1). The case-fatality ratio during 1998–2000 was 5 times
lower than the case-fatality ratio reported in 1947 (91%).
Epidemiology
During 1998–2000, >1 case of tetanus was reported by 31
states (Figure 2). Six states reported tetanus cases in each of
the 3 years (California, Florida, Michigan, Pennsylvania, Texas,
and Wisconsin). Nineteen states and the District of Colum-
bia reported no cases of tetanus. Eight states with no reported
cases were in the Rocky Mountain and West North Central
regions, where the incidence of reported tetanus has histori-
cally been low (1,16–20), and no cases of tetanus were
reported from New England (Figure 2).
Age and sex were reported for all 130 cases; race was
reported for 111 (85%) and ethnicity for 123 (95%) of 130
cases. Twelve (9%) of the cases were aged <20 years (includ-
ing one neonate); 71 (55%) were aged 20–59 years; and 47
(36%) were aged >60 years (Figure 3). The average annual
incidence of tetanus during 1998–2000 was 0.05 cases per
million population among persons aged <20 years, 0.16 cases
per million population among adults aged 20–59 years, and
0.35 cases per million population among adults aged >60 years.
FIGURE 1.  Tetanus morbidity and mortality rates, by year —
United States, 1947–2000
Source: Data from the National Notifiable Disease Surveillance System,
CDC, Atlanta, GA.
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FIGURE 2.  Number of tetanus cases reported and average
annual incidence rates, by state — United States, 1998–2000
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FIGURE 3.  Number of tetanus cases reported, average annual
incidence rates, and survival status of patients, by age group
— United States, 1998–2000
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Seventy-eight cases (60%) were male. The differences in inci-
dence rates between males and females varied by age group.
For persons aged <20 years, the incidence of tetanus among
males (0.08 cases per million population) was 2.7 times the
incidence among females (0.03 cases per million population).
For persons aged 20–59 years, the incidence of tetanus among
males (0.23 cases per million population) was 2.9 times the
incidence among females (0.08 cases per million population).
For persons aged >60 years, the incidence of tetanus was 0.31
cases per million population among males, lower than the
incidence of 0.39 cases per million population among females.
The incidence of tetanus among non-Hispanic whites was
0.13 cases per million population (78 cases); among non-
Hispanic blacks, 0.12 cases per million population (12 cases);
among Asian/Pacific Islanders, 0.10 cases per million popu-
lation (three cases); and among Native American/Alaska
Natives, 0.16 cases per million population (one case). The
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* Other puncture wounds included injuries from a screwdriver, awl, rake,
pencil, rose bush, and lawnmower.
incidence of reported tetanus among persons with Hispanic
ethnicity was 0.38 cases per million population (36 cases)
during 1998–2000, compared with 0.27 cases per million
during 1995–1997 (1).
The 20 reported deaths occurred among patients aged
33–88 years. Seventy-five percent (15/20) of the patients who
died were aged >60 years. The case-fatality ratio among
patients with known outcome aged >60 years was 40% (15/
38), compared with 8% (5/63) among patients with known
outcome aged 20–59 years.
Tetanus Toxoid Vaccination
During 1998–2000, the number of doses of tetanus toxoid
previously received was reported for 38% (50/130) of patients,
compared with 47% (58/124) during 1995–1997 (1). Eight
of 50 patients (16%) with known vaccination history (6% of
all cases) during 1998–2000 had received >3 doses of tetanus
toxoid with the last dose <10 years before the onset of tetanus
(Table 1). All eight patients had nonwork-related acute inju-
ries; six did not seek medical care before the onset of tetanus,
and three were aged <20 years.
Twenty patients were reported to have received at least a
primary series of tetanus toxoid; 18 had an outcome reported.
Of these 18 patients, one (6%) death occurred; the death was
in an injection-drug user (IDU) whose last dose of tetanus
toxoid was 11 years before the onset of tetanus. A total of 110
patients reported <3 doses of tetanus toxoid or had an
unknown vaccination history; 95 of these patients had an out-
come reported. Nineteen deaths (20%) occurred among these
95 patients.
Type of Injury, Wound Treatment,
and Prophylaxis
Among 129 patients with information provided on the con-
dition leading to tetanus, acute trauma was reported for 73%
TABLE 1. Tetanus toxoid vaccination history, time since last dose, and deaths among 130 reported cases of tetanus — United
States, 1998–2000
Time since last dose* Case fatality ratio†
Vaccination history No.      (%) <10 years >10 years Unknown No. deaths/No. cases (%)
0 doses 20§ (15.4) — — — 1/16 (6)
1 dose 10 (7.7) 2 8 0 0/9 (0)
2 doses 0 (0.0) 0 0 0 0/0 (0)
3 doses 2 (1.5) 2 0 0 0/2 (0)
>4 doses 18 (13.9) 6 8 4 1/16 (6)¶
Unknown 80** (61.5) 6 17 57 18/70 (28)
Total 130 (100.0) 16 33 61 20/113 (18)
* Number of cases.
† The outcome was known for 113 of 130 cases.
§ Includes one neonatal case.
¶ Death occurred in an injection-drug user aged 55 years; 11 years since last dose.
** Includes cases with unknown total number of doses who could recall when the last dose of vaccine was received.
(94/129) of patients; no acute injury (i.e., patients with
abscesses, ulcers, or gangrene) was reported for 26% (34/129);
and one case (1%, 1/129) was reported in a neonate (Table 2).
A puncture wound was the most frequent type of acute trauma
(50%), followed by lacerations (33%) and abrasions (9%).
Puncture wounds included stepping on a nail (15 cases), splin-
ter (five cases), injury from barbed wire (five cases), a tattoo
(one case), and a spider bite (one case).* The acute injury was
located on the lower extremity in 48 (51%) patients, the
upper extremity in 34 (36%) patients, the head or trunk in
nine (10%) patients, and not specified in three patients. The
environment in which the acute injury occurred was reported
for 83 (88%) patients. Thirty-seven (45%) patients were
injured at home or indoors; 26 (31%) were injured while farm-
ing or gardening; 19 (23%) were injured while engaging in
other outdoor activities; and one (1%) was injured in an
automobile accident.
Ninety (96%) of the 94 patients with an acute injury had
information reported regarding medical care for the injury.
Of these 90 patients, 33 (37%) sought care for the acute injury.
Tetanus toxoid prophylaxis for wound management was
administered to 20 patients (19 of whom were eligible
according to ACIP recommendations [21]); no tetanus tox-
oid was administered to 12 patients (11 of whom were eli-
gible); and information was not available for one patient.
Therefore, 63% (19/30) of eligible patients who sought care
received tetanus toxoid prophylaxis.
Clinical Features and Treatment
The median interval between the acute injury reported to
have led to tetanus and the onset of tetanus was 7 days (range:
0–112 days) for the 89 nonneonatal patients with a known
Vol. 52 / SS-3 Surveillance Summaries 5
FIGURE 4.  Number of tetanus cases reported among persons
with diabetes or injection-drug use (IDU), by age group —
United States, 1998–2000
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TABLE 2. Condition before the onset of tetanus, by acute injury
status and number of cases with a history of injection-drug
use (IDU) and diabetes, among 130 reported tetanus cases —
United States 1998–2000
Tetanus Tetanus All
Condition before among among tetanus
 tetanus diabetics IDUs Other* cases
Acute injury
Puncture 7 1 39 47
Laceration 2 0 29 31
Abrasion 0 0 8 8
Crush 1 0 2 3
Avulsion 0 0 1 1
Compound fracture 0 0 1 1
Gunshot 0 0 1 1
Unknown 1 0 1 2
Total 11 1 82 94
No acute injury
Abscess 0 7 0 7
Ulcer 2 2 3 7
Gangrene 2 0 0 2
Cellulitis 0 1 0 1
Gingivitis 0 0 3 3
Other infection(s) 0 1 1 2
No infection† 1 7 4 12
Total 5 18 11 34
Neonate 0 0 1 1
Unknown injury
 history 0 0 1 1
TOTAL 16 19 95 130
* Tetanus cases that did not occur among diabetics or injection-drug users.†Patients without a reported injury.
date of injury. The time between the injury and the onset of
symptoms was <30 days for 84 (94%) of the patients. Eleven
(12%) patients reported an injury <2 days before the onset of
tetanus.
The type of tetanus was reported for 115 patients; 93 (81%)
had generalized, 20 (17%) had localized, and two (2%) had
cephalic tetanus. Generalized tetanus was the most common
type reported among all age groups. The vaccination history
was known for 40 (43%) patients with generalized tetanus
and seven (35%) patients with localized tetanus. Thirteen
(14%) patients with generalized tetanus and five (25%) patients
with localized tetanus had received >3 doses of tetanus toxoid.
Tetanus immune globulin (TIG) was reported to have been
given for treatment of tetanus in 125 patients. Time between
reported onset of tetanus and administration of TIG for 121
(97%) patients with information was <24 hours after onset
for 32 patients, 1–4 days after onset for 59 patients, and >4
days after onset for 30 patients.
Information regarding hospitalization was reported for 119
(92%) of 130 cases. Of the 115 (97%) hospitalized patients,
the median length of hospitalization was 19 days (range: 1–123
days). Of the 95 patients with information available on
whether or not mechanical ventilation was used, 52 (55%)
received mechanical ventilation. Sixteen (31%) of those who
required mechanical ventilation died; four (9%) of those who
were not mechanically ventilated died.
Neonatal Tetanus
One neonate, delivered in a hospital, developed generalized
tetanus on the ninth day of life. The infant had an infected
umbilical cord that had been treated with bentonite clay for
cord care at home. TIG therapy was administered within 24
hours of the onset of tetanus, and the baby recovered after 19
days of hospitalization. The baby’s U.S.-born mother had a
philosophic objection to vaccination and had received no teta-
nus toxoid (22).
Tetanus Among Diabetics and IDUs
Diabetic patients constituted 12% (16/130) of the 130
reported cases of tetanus during 1998–2000 (Figure 4), com-
pared with 2% of cases during 1995–1997 (1). The median
age of the diabetic patients during 1998–2000 was 72 years
(range: 42–84 years). The average annual incidence rate of
tetanus among persons known to have diabetes was 0.26 cases
per million population (four cases) for adults aged 20–59 years
and 0.70 cases per million population (12 cases) for adults
aged >60 years. Eleven (69%) of the diabetic patients were
male; seven (44%) were from Texas; and four (25%) were
Hispanic. The vaccination history was reported for two (13%)
patients. One patient had received a primary series at an
unknown time before the onset of tetanus, and the other
patient had received a single lifetime dose of tetanus toxoid 4
years before the onset of tetanus. Eleven of the 16 patients
with diabetes had an acute injury; four had gangrene or ulcer;
and one had no wound reported. Only two patients, both
with a puncture wound, sought medical attention before the
6 MMWR June 20, 2003
onset of tetanus. Five (31%) of the 16 patients with diabetes
died.
IDUs accounted for 15% (19/130) of the tetanus cases
(Figure 4). The median age of these patients was 41 years
(range: 27–57 years); eight patients (42%) were aged 30–39
years. Fifteen (79%) of the patients were male; 16 (84%) were
from California; and 14 (74%) were Hispanic. Of the 19 cases
among IDUs reported from all states, 14 (74%) used heroin;
10 (53%) reported injecting black tar heroin, a low-grade res-
inous form of heroin (23). The vaccination history was
reported for five (26%) patients. Of these patients, three had
received a primary series and a booster dose, with the last
dose of tetanus toxoid received either >10 years before the
onset of tetanus or at an unknown time before the onset of
tetanus; one patient had received a single lifetime dose of teta-
nus toxoid 9 years before the onset of tetanus, and one
patient had not been vaccinated. Only one patient among the
19 IDUs reported an acute injury. Four (21%) of the 19 IDUs
died.
Discussion
Tetanus is an uncommon but severe disease that occurs pri-
marily among persons who are unvaccinated or inadequately
vaccinated. The average annual incidence of tetanus during
1998–2000 was 25% lower than that reported in the late 1980s
and 96% lower than that reported in 1947. The age distribu-
tion of reported tetanus cases among adults shifted during
the late 1990s, primarily because of an overall decrease in the
number of cases among older adults, without a substantial
reduction in cases among young and middle-aged adults. Per-
sons aged >60 years accounted for 36% of cases during 1995–
2000, compared with 52%–61% of cases during 1982–1994
(1,16–20).
During 1998–2000, the highest rates of tetanus and
tetanus-related deaths were among adults aged >60 years. The
immune response to tetanus toxoid can be less robust with
increasing age, particularly among adults with chronic condi-
tions (24,25). A national population-based seroprevalence
survey during 1988–1994 indicated that 69% of adults aged
>70 years lacked protective levels of tetanus antibody, com-
pared with 9% of children aged 6–11 years (10). Certain older
adults probably missed booster vaccinations, and others might
not have received a primary series of tetanus toxoid.
IDUs comprised 15%–18% of the tetanus cases during
1995–2000, compared with 2.1%–4.5% during 1982–1994
(1,16–20). During this period, the majority of the tetanus
cases among IDUs was reported among young and middle-
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aged adults and accounted for 27% of tetanus patients aged
20–59 years (1). Injection-drug use has been associated with
an increased risk of tetanus (26–28). The majority of IDUs
among the tetanus patients during 1998–2000 had no his-
tory of an acute injury, and a high proportion of patients
reported injection of black-tar heroin. Contaminated drugs,
adulterants (e.g., sugar, quinine, rat poison, laxative, and other
illegal drugs), unsanitary injection equipment and practices,
and altered immunity might contribute to an increased risk
of tetanus among IDUs (23,26,28,29). Moreover, the high
incidence of tetanus among Hispanics during 1998–2000 is
partly attributable to the cases among IDUs, many of whom
were Hispanic.
Vaccination history was known for <60% of tetanus
patients reported from 1982–2000. During 1998–2000, only
6% of all tetanus patients were known to have been up-to-
date with tetanus toxoid vaccination. No deaths occurred
among these vaccinated patients. This finding is consistent
with previous reports that illness is less severe among patients
who have a history of receiving at least a primary series of
tetanus toxoid compared with tetanus among inadequately
vaccinated or unvaccinated patients (2).
Tetanus among children is uncommon in the United States.
However, 13 nonneonatal cases occurred among patients aged
<15 years during 1992–2000. Of these, 85% (11/13) were
among children whose parents objected to vaccination (30).
Before 1998, the two most recent cases of neonatal tetanus
reported in the United States occurred among infants born in
1989 and in 1995 to immigrant mothers with incomplete
tetanus toxoid vaccination (31,32). The mother of the neo-
nate with tetanus in 1998 was born in the United States but
had not received tetanus toxoid because of philosophical
objection to vaccination (22). Protection of neonates against
tetanus depends on passive transfer of maternal antibody from
vaccinated mothers. Spores of Clostridium tetani are ubiqui-
tous, and tetanus usually results after contamination of the
umbilical cord (2).
Tetanus contracted after mild injuries or abrasions has pre-
viously been recognized and can result when patients do not
seek medical attention or receive appropriate wound manage-
ment (1,18–20,33). Among patients with acute injuries and
known medical care history reported from 1998–2000, only
37% sought medical attention for the acute injury; of those
who did seek medical attention, only 63% of those eligible
received tetanus toxoid as wound prophylaxis. Many of the
injuries were probably perceived as mild and occurred in per-
sons inadequately vaccinated.
Surveillance for tetanus has some limitations. Because no
confirmatory laboratory test exists, the diagnosis is made on
clinical grounds and with the exclusion of other possible causes
of illness. Anaerobic cultures of tissues or aspirates yield
C. tetani among only a minority of tetanus patients (34,35).
CDC relies on passive reporting of cases by physicians to state
and local health departments, and no recent evaluation of the
completeness of tetanus case reporting to CDC has been per-
formed. However, the completeness of reporting of tetanus
deaths was evaluated in the 1980s (36). At that time, an esti-
mated 40% of deaths were reported to CDC, and other data
indicated that the completeness of reporting of tetanus mor-
bidity might have been even lower. Surveillance for tetanus
has remained essentially unchanged, and the national surveil-
lance system continues to be valuable for identifying and follow-
ing trends in tetanus disease.
For approximately 50 years, the recommendation that per-
sons receive a primary 3-dose series of tetanus toxoid-
containing vaccine and a booster dose every 10 years has proven
to be effective in preventing tetanus or modifying its severity
(2). The majority of the tetanus cases during 1998–2000
occurred among persons who were not appropriately vacci-
nated against tetanus or who had an unknown vaccination
history. Disease-reduction goals for the United States include
elimination of tetanus among persons aged <35 years by the
year 2010 (37). Although a shortage of tetanus and diphthe-
ria toxoids vaccine in the United States began in the last quar-
ter of 2000, sufficient supplies of vaccine have been available
to resume routine vaccination since 2002 (38). Health-care
providers should evaluate their patients’ tetanus vaccination
status at each encounter and vaccinate as needed, which is
critical among those patients in high-risk groups (e.g., older
persons, diabetics, IDUs, persons with Hispanic ethnicity,
pregnant women, persons with philosophical objections to
vaccines, and persons who might not have received a primary
series [e.g., immigrants]).
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This report summarizes West Nile virus (WNV) surveillance
data reported to CDC through ArboNET and by states and
other jurisdictions as of August 7, 2002.
United StatesDuring the reporting period of July 31–August 7, a total of
68 laboratory-positive human cases of WNV-associated ill-
ness were reported from Louisiana (n=40), Mississippi (n=23),
Texas (n=four), and Illinois (n=one). During the same
period, WNV infections were reported in 447 dead crows,
263 other dead birds, 42 horses, and 183 mosquito pools.
During 2002, a total of 112 human cases with laboratory
evidence of recent WNV infection have been reported from
Louisiana (n=71), Mississippi (n=28), Texas (n=12), and Illi-
nois (n=one). Five deaths have been reported, all from Louisi-
ana. Among the 98 cases with available data, 59 (60%)
occurred among men; the median age was 55 years (range:
3–88 years), and the dates of illness onset ranged from June 10
to July 29.In addition, 1,076 dead crows and 827 other dead birds
with WNV infection were reported from 34 states, New York
City, and the District of Columbia (Figure 1); 87 WNV
infections in horses have been reported from 12 states
(Alabama, Florida, Georgia, Illinois, Kentucky, Louisiana,
Minnesota, Mississippi, North Dakota, South Dakota, Ten-
nessee, and Texas). During 2002, WNV seroconversions have
been reported in 52 sentinel chicken flocks from Florida,
Nebraska, and Pennsylvania; and 425 WNV-positive mos-
quito pools have been reported from 12 states (Alabama, Geor-
gia, Illinois, Indiana, Massachusetts, Mississippi, New Jersey,
Ohio, Pennsylvania, South Dakota, Texas, and Virginia), New
York City, and the District of Columbia.
West Nile Virus Activity — United States, July 31–August 7, 2002,
and Louisiana, January 1–August 7, 2002
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